Brokers Offer Predictions for Alnylam Pharmaceuticals, Inc.’s FY2017 Earnings (ALNY)
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Equities research analysts at B. Riley lowered their FY2017 earnings estimates for Alnylam Pharmaceuticals in a report released on Monday. B. Riley analyst M. Kumar now expects that the biopharmaceutical company will post earnings per share of ($5.32) for the year, down from their previous estimate of ($5.07). B. Riley has a “Buy” rating and a $205.00 price target on the stock. B. Riley also issued estimates for Alnylam Pharmaceuticals’ Q4 2017 earnings at ($1.60) EPS, Q2 2018 earnings at ($1.46) EPS, Q3 2018 earnings at ($1.14) EPS, Q4 2018 earnings at ($1.20) EPS and FY2018 earnings at ($4.90) EPS.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The business had revenue of $17.10 million during the quarter, compared to analysts’ expectations of $28.15 million. During the same quarter in the previous year, the business posted ($1.21) EPS. The company’s quarterly revenue was up 24.8% on a year-over-year basis.
Several other analysts also recently issued reports on the stock. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $182.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Sunday. Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “conviction-buy” rating in a research report on Friday, December 15th. BidaskClub downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Cowen reaffirmed a “buy” rating and issued a $151.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, November 9th. Finally, Morgan Stanley increased their price objective on shares of Alnylam Pharmaceuticals from $101.00 to $130.00 and gave the company an “equal weight” rating in a research report on Thursday, November 9th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $121.20.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at $130.74 on Wednesday. Alnylam Pharmaceuticals has a 1-year low of $35.98 and a 1-year high of $147.63. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83. The company has a market cap of $12,860.00, a P/E ratio of -24.90 and a beta of 2.98.
A number of institutional investors have recently added to or reduced their stakes in the business. FMR LLC boosted its holdings in Alnylam Pharmaceuticals by 6.3% in the second quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock worth $1,094,559,000 after purchasing an additional 815,270 shares during the period. Vanguard Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 13.4% in the second quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock worth $512,020,000 after purchasing an additional 759,295 shares during the period. BlackRock Inc. boosted its holdings in Alnylam Pharmaceuticals by 9.3% in the second quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock worth $413,811,000 after purchasing an additional 441,957 shares during the period. Orbimed Advisors LLC boosted its holdings in Alnylam Pharmaceuticals by 69.7% in the third quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock worth $127,453,000 after purchasing an additional 445,600 shares during the period. Finally, First Trust Advisors LP boosted its holdings in Alnylam Pharmaceuticals by 25.3% in the third quarter. First Trust Advisors LP now owns 784,619 shares of the biopharmaceutical company’s stock worth $92,185,000 after purchasing an additional 158,288 shares during the period. 88.39% of the stock is owned by hedge funds and other institutional investors.
In other Alnylam Pharmaceuticals news, SVP Laurie Keating sold 30,000 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, December 1st. The shares were sold at an average price of $135.89, for a total value of $4,076,700.00. Following the completion of the transaction, the senior vice president now owns 41,500 shares of the company’s stock, valued at $5,639,435. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Michael Mason sold 36,745 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the completion of the transaction, the vice president now directly owns 6,352 shares of the company’s stock, valued at approximately $835,859.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 274,075 shares of company stock valued at $35,356,089. 4.30% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This piece was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2018/01/10/brokers-offer-predictions-for-alnylam-pharmaceuticals-inc-s-fy2017-earnings-alny.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.